हिंदी में पढ़ें

Aurobindo Pharma

Aurobindo Pharma unit gets first product approval from USFDA

Aurobindo Pharma unit gets first product approval from USFDA

Wed, Sep 11, 2024

The new injectable facility of Eugia Steriles, a subsidiary of Eugia Pharma Specialities and a stepdown unit of the company, situated at Anakapalli District of Andhra Pradesh was inspected by the US FDA from March 28 to April 5 this year.

Aurobindo Pharma arm gets warning letter from USFDA for formulations unit in Telangana

Aurobindo Pharma arm gets warning letter from USFDA for formulations unit in Telangana

Fri, Aug 16, 2024

Aurobindo Pharma Ltd's subsidiary Eugia Pharma Specialities Ltd has received a warning letter from the USFDA for its Telangana-based formulation manufacturing unit. This follows the unit's earlier classification as 'Official Action Indicated' (OAI). Despite this, the company assures there is no impact on current US market supplies and remains committed to improving compliance with FDA regulations.

Analyzing Aurobindo Pharma's Recent Action

Analyzing Aurobindo Pharma's Recent Action

Mon, Jul 15, 2024

Why is Aurobindo Pharma in action? Board meeting on July 18, big decision possible. Know complete details from Nupur.

TRENDING NOW

DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer

DGGI acts on pharma companies for GST evasion; Dr Reddy's, Glenmark, Aurobindo Pharma, Mylan and Cipla come under hammer

Wed, Mar 30, 2022

Directorate General of GST Intelligence (DGGI) which works under the aegis of the Ministry of Finance has taken action against many big pharma companies in the country for not filing Goods and Services Tax (GST). The pharma giants included are Dr. Reddys Laboratories, Glenmark, Aurobindo Pharma, Mylan and Cipla, as reported by Zee Business’s Tarun Sharma.

Aurobindo Pharma shares jump 6.5% after company terminates pact with Cronus Pharma to buy controlling stake

Aurobindo Pharma shares jump 6.5% after company terminates pact with Cronus Pharma to buy controlling stake

Mon, Aug 23, 2021

Aurobindo Pharma’s share price soared 6.5 per cent at Rs 726 per share on the BSE intraday trade on Monday after the company terminated the pact with Cronus Pharma to acquire a 51 per cent ownership stake.

Aurobindo Pharma shares fall almost 9% amid weak US business and below estimate Q1 numbers

Aurobindo Pharma shares fall almost 9% amid weak US business and below estimate Q1 numbers

Fri, Aug 13, 2021

Aurobindo Pharma share price on Friday cracked almost 9 per cent at Rs 754.45 per share on the BSE intraday trade as the company posted a poor operational performance in the first quarter of the financial year on the back of a decline in the US market and antiretroviral (ARVs).

Stocks to Watch: Aurobindo Pharma – BUY - Restructuring to bring windfall gains, analyst says; valuations low against peers; target price Rs 1200-1250

Stocks to Watch: Aurobindo Pharma – BUY - Restructuring to bring windfall gains, analyst says; valuations low against peers; target price Rs 1200-1250

Sun, Jul 04, 2021

The stocks of Aurobindo Pharma gained on Friday riding on the news of company’s restructuring plans. This stock ended around Rs 994 on the NSE. Under the restructuring plans, Aurobindo Pharma board has given its approval to transfer its Unit-4 which is related to its injectable business to its subsidiary Eugia Pharma Specialties

STOCK OF THE DAY: HERE IS WHY Market Guru Anil Singhvi suggests to BUY Aurobindo Pharma Futures shares – check target price here

STOCK OF THE DAY: HERE IS WHY Market Guru Anil Singhvi suggests to BUY Aurobindo Pharma Futures shares – check target price here

Fri, Jul 02, 2021

Zee Business Managing Editor and Market Guru Anil Singhvi picks Aurobindo Pharma Futures as stock of the day with a Buy suggestion, as the company announces restructuring of its business.

ZEE BIZ EXCLUSIVE: Aurobindo Pharma likely to announce demerger of its injectables business in 1-2 weeks; Market Guru Anil Singhvi sees it as a big value creation for company

ZEE BIZ EXCLUSIVE: Aurobindo Pharma likely to announce demerger of its injectables business in 1-2 weeks; Market Guru Anil Singhvi sees it as a big value creation for company

Wed, Jun 16, 2021

A big news emerging from the stable of Aurobindo Pharma. The company is planning a demerger of its injectables business. The company could announce about it over the next 1-2 weeks. The proposal has been submitted to the company’s board and there could be a meeting soon. Zee Business Executive Editor Swati Khandelwal brings this Exclusive news. Know full details here!

Market cap nearly Rs 60k cr! Aurobindo Pharma share price rises nearly 5% - Day high! Know key triggers for stock

Market cap nearly Rs 60k cr! Aurobindo Pharma share price rises nearly 5% - Day high! Know key triggers for stock

Fri, Jun 11, 2021

Aurobindo Pharma share price today is Rs 1009, up Rs 45 or 4.6%. Aurobindo Pharma’s market cap is near Rs 60000 cr. The 52 week low on the stock is Rs 738. The stock is trading near the day’s high today and the 52 week high on the stock is Rs 1063.9

Aurobindo Share price: Sharekhan says BUY, pegs target at Rs 1185

Aurobindo Share price: Sharekhan says BUY, pegs target at Rs 1185

Tue, Jun 01, 2021

Sharekhan says that Aurobindo Pharma reported a weak performance for the quarter and the adjusted PAT missed estimates. Sales for the quarter at Rs 6002 cr declined by 2.5% yoy, attributable to a 3.6% drop in the formulations segment owing to a 4.5% yoy decline in the US while Europe sales were lower by 6% yoy. The API sales were up 5% yoy for the quarter. The operating profits for the quarter at Rs 1274.6 cr, declined by 5% yoy, while the operating margins 21.2% declined by 56bps yoy and missed estimates

JPMorgan on Aurobindo Pharma stock re-rating trigger and target price

JPMorgan on Aurobindo Pharma stock re-rating trigger and target price

Thu, Apr 22, 2021

In its report, JPMorgan says that the injectables business of Aurobindo Pharma includes the $1.4bn U.S. franchise (likely the best profitability among peers), EUR700+Mn European operation (largest EU player from India), RoW and an API business. Even assuming a generics business multiple of 8-9x, Aurobindo Pharma's business could be valued at Rs 1,400 - 1,500/share. This does not capture the upside from its complex pipeline investment (respiratory, biosimilar or API growth from PLI scheme)

Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma

Stock Of The Day: Anil Singhvi reveals his top recommendation for investors today - Aurobindo Pharma

Thu, Apr 08, 2021

Aurobindo Pharma share price today: Zee Business Managing Editor Anil Singhvi has said today that Pharma shares will remain in focus going forward. Singhvi said that from next week the results season will start

Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100

Aurobindo Pharma share price: Sharekhan retains Buy recommendation with price target of Rs 1100

Wed, Mar 31, 2021

Aurobindo Pharma’s US business is expected to stage a marked improvement. A mix of factors, which includes a sturdy pipeline of new products, expected traction in the lucrative injectables space driven by strong new product pipeline and commissioning of a new facility coupled with growth in the recently launched products would boost US business’ sales

SBI, Ashok Leyland, ACC, IRCTC, Aurobindo Pharma: Technical Analysis for traders in top stocks

SBI, Ashok Leyland, ACC, IRCTC, Aurobindo Pharma: Technical Analysis for traders in top stocks

Wed, Mar 31, 2021

Ashis Biswas, Head of Technical Research at CapitalVia Global Research has revealed trading strategies in SBI, Ashok Leyland, ACC, IRCTC and Aurobindo Pharma. Ashis has highlighted the reason for the trade and also mentioned the stop-loss in these counters.

Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100

Aurobindo Pharma Share price: Sharekhan retains their Buy recommendation with a revised Price target of Rs 1100

Fri, Feb 12, 2021

Aurobindo Pharma Q3 FY21 revenue, operating profits and PAT were a tad below the estimates. Sales at Rs 6365 cr is up 8% yoy (slightly below estimates), attributable to an 11.3% yoy growth in the formulations segment, while API sales were down 13.6% yoy. OPM expanded by 100 BPS yoy to 21.5% (estimated OPM 22%) led by a 310 bps expansion in gross margins, which were partly offset by an increase in other expenses.

Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC

Aurobindo Pharma, Biocon, Dr Reddy’s Lab and Divi’s Laboratories: Resilient demand points to another good year for Pharma Sector says HSBC

Thu, Jan 21, 2021

After four difficult years, the India pharma sector rallied in 2020, and HSBC expects the benign operating environment to lead to another good year. HSBC revised their estimates and target prices, and rolled forward our valuations to December 2022e from September 2022e. HSBC also preview Q3 FY21e results, where they expect the recovery to continue for most of the companies that HSBC covers.

Nifty to Sensex - All you need to know about markets today

Nifty to Sensex - All you need to know about markets today

Wed, Nov 25, 2020

Banking and financial stocks dragged the most while IT and pharma stocks also weighed on the indices. The Sensex declined by 1.6% or 695 points to 43828. The Nifty plunged by 1.5% or 197 points to 12858. The Nifty sees its biggest 1-day fall in nearly 5 months.

Key Covid-19 vaccines India banking on-Oxford/AstraZeneca, Novavax | Credit Suisse highlights Aurobindo Pharma, Apollo Hospitals stocks

Key Covid-19 vaccines India banking on-Oxford/AstraZeneca, Novavax | Credit Suisse highlights Aurobindo Pharma, Apollo Hospitals stocks

Wed, Nov 11, 2020

India needs about 1.7 bn COVID-19 vaccine doses to vaccinate the majority of its adult population. It targets to administer 400-500 mn doses by July 2021. The key vaccines India is banking on are from Oxford/AstraZeneca, Novavax and J&J (temperature range is 2-8°C) and the earliest efficacy data is expected by end of Nov 2020/Dec 2020 and in the best case, vaccines can be rolled out in Jan 2021.

Stock Market Today: Sensex, Nifty dip after range-bound intraday trade; Bharti Airtel, Aurobindo Pharma shares bleed

Stock Market Today: Sensex, Nifty dip after range-bound intraday trade; Bharti Airtel, Aurobindo Pharma shares bleed

Thu, Aug 13, 2020

Stock Market Today: The BSE Sensex lost 59 points and closed at 38,310 mark while the NSE Nifty went down 7 points and closed at 11,300 levels. Bank Nifty index went down 67 points and closed at 22,196 mark.

Aurobindo Pharma share price: Most early gains given up, but still closes over 1 pct higher

Aurobindo Pharma share price: Most early gains given up, but still closes over 1 pct higher

Fri, Jun 05, 2020

Aurobindo Pharma share price: Shares of Aurobindo Pharma on Thursday gave up most of their early gains on profit-booking and closed over 1 per cent higher.

Stocks in Focus on June 4: BPCL, HDFC Life to Pharma Companies; here are expected newsmakers of the day

Stocks in Focus on June 4: BPCL, HDFC Life to Pharma Companies; here are expected newsmakers of the day

Thu, Jun 04, 2020

Stocks in Focus on June 4: BPCL, HDFC Life, Aurobindo Pharma, Sun Pharma, etc. are expected to remain newsmakers throughout the intraday trade session.

Why Aurobindo Pharma-Sandoz deal fell apart? Check brokers' reactions

Why Aurobindo Pharma-Sandoz deal fell apart? Check brokers' reactions

Fri, Apr 03, 2020

Hyderabad-based Aurobindo Pharma's decision to break its deal with Sandoz will likely impact the company and its stocks according to analysts who track the sector. The biggest reason why this decision has been taken is due to the company not getting approval from US Federal Trade Commission (FTC)

Load More

LIVE TV

By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.

x